• 1. Excellent mechanical performance and enhanced dielectric properties of OBC/SiO2 elastomeric nanocomposites: effect of dispersion of the SiO2 nanoparticles?
  Xing Zhao,Lu Bai,Rui-Ying Bao,Zheng-Ying Liu,Ming-Bo Yang,Wei Yang RSC Adv., 2017,7, 46297-46305
• 2. Evolution study of photo-synthesized gold nanoparticles by spectral deconvolution model: a quantitative approach
  Chung-Sung Yang,Mong-Shian Shih,Fang-Yi Chang New J. Chem., 2006,30, 729-735
• 3. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341
• 4. Exciplex emission from the mixed dimer of naphthalene and 2-cyanonaphthalene in a supersonic jet
  Aloke Das,K. K. Mahato,Chayan K. Nandi,Tapas Chakraborty,Shridhar R. Gadre,Nikhil A. Gokhale Phys. Chem. Chem. Phys., 2002,4, 2162-2168
• 5. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608

Introduction to (3-Cyano-5-methoxyphenyl)boronic Acid (CAS No. 960589-15-5)

(3-Cyano-5-methoxyphenyl)boronic acid, with the CAS number 960589-15-5, is a specialized organic compound that has garnered significant attention in the field of chemical biology and pharmaceutical research. This compound, characterized by its unique structural features, plays a crucial role in various synthetic applications, particularly in the development of novel therapeutic agents and biomaterials.

The molecular structure of (3-Cyano-5-methoxyphenyl)boronic acid consists of a phenyl ring substituted with a cyano group at the 3-position and a methoxy group at the 5-position, along with a boronic acid functional group. This specific arrangement of functional groups makes it a versatile intermediate in organic synthesis, enabling its use in cross-coupling reactions such as the Suzuki-Miyaura coupling, which is widely employed in the construction of complex molecular architectures.

In recent years, there has been a surge in research focused on boronic acid derivatives due to their remarkable reactivity and stability. The boronic acid moiety is particularly valuable in medicinal chemistry because it can participate in reversible binding interactions with various biological targets. This property has been leveraged to develop innovative drug candidates that exhibit high selectivity and low toxicity.

One of the most compelling applications of (3-Cyano-5-methoxyphenyl)boronic acid is in the synthesis of targeted therapeutics. Researchers have utilized this compound to develop small molecule inhibitors that modulate enzyme activity and signal transduction pathways. For instance, studies have shown that derivatives of this compound can inhibit kinases and other enzymes implicated in cancer progression. The cyano group enhances the electrophilicity of the boronic acid moiety, facilitating its incorporation into biologically active molecules.

The methoxy group at the 5-position of the phenyl ring contributes to the overall solubility and bioavailability of the compound, making it an attractive scaffold for drug design. Additionally, the presence of both electron-withdrawing and electron-donating groups allows for fine-tuning of physicochemical properties, such as pKa and lipophilicity, which are critical factors in determining drug efficacy.

Recent advancements in computational chemistry have further highlighted the potential of (3-Cyano-5-methoxyphenyl)boronic acid as a building block for drug discovery. Molecular modeling studies have demonstrated that this compound can be incorporated into highly specific binding motifs that interact with target proteins. These studies have provided valuable insights into how structural modifications can enhance binding affinity and reduce off-target effects.

The pharmaceutical industry has also explored the use of (3-Cyano-5-methoxyphenyl)boronic acid in the development of diagnostic agents. Boron-containing compounds are known for their ability to participate in positron emission tomography (PET) imaging, making them useful for detecting diseases at an early stage. Researchers have synthesized radiolabeled derivatives of this compound that exhibit high sensitivity and specificity in imaging studies.

In conclusion, (3-Cyano-5-methoxyphenyl)boronic acid (CAS No. 960589-15-5) is a multifaceted compound with significant potential in pharmaceutical research and development. Its unique structural features make it an invaluable tool for synthesizing novel therapeutics and diagnostic agents. As research continues to uncover new applications for this compound, its importance in advancing medical science is likely to grow even further.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)